Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Timolol Gel Clear all

Conditions: Infantile Hemangiomas
Interventions: Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 8 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Wound of Skin, Wound Heal, Wound Open, Surgical Wound
Interventions: 0.25% Timolol gel with paraffin gauze dressings, Vaseline dressing; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hereditary Hemorrhagic Telangiectasia
Interventions: Timolol Gel, Placebo Gel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hemangioma
Interventions: timolol maleate 0.5% gel; Drug
Lead sponsor: Rady Children's Hospital, San Diego; Other
Eligibility: 7 Days to 6 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Week to 5 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Infantile Hemangiomas
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Month to 5 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound
Interventions: Timolol, Non biologically active gel; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Infantile Hemangioma
Interventions: 0.25% Timolol Maleate Gel Forming Solution, 0.5% Timolol Maleate Gel Forming Solution; Drug
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: Up to 84 Days
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 9 more

Conditions: Wound of Skin, Wound Heal, Surgical Wound, Full Thickness Skin Graft Healing
Interventions: 0.25% timolol gel with full-thickness skin grafts, Vaseline dressing; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Open Angle, Ocular Hypertension
Interventions: Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Bourbonnais, Illinois • Charlotte, North Carolina

Conditions: Sturge Weber Syndrome, Port-wine Mark
Interventions: Timolol, Preservative free artificial tear gel.; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 2 Years to 10 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Open-Angle, Chronic Wounds
Interventions: Timolol Maleate; Drug
Lead sponsor: VA Northern California Health Care System; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mather, California

Conditions: Infantile Hemangioma, Very Low Birth Weight Infants
Interventions: topical 0.5% Timolol maleate, Control (placebo) group; Drug
Lead sponsor: Alice K. Gong; Other
Eligibility: Up to 6 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds

Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

Adjunctive Study of AL-37807 Ophthalmic Suspension

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities

Beta Adrenergic Antagonist for the Healing of Chronic DFU

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Absorption and Safety of Topical Timolol to Treat Chronic Wounds

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)